Biostatistics and Bioinformatics in Clinical Trials
暂无分享,去创建一个
[1] Donald A. Berry,et al. Statistical Innovations in Cancer Research , 2003 .
[2] Shuguang Huang,et al. Comparison of false discovery rate methods in identifying genes with differential expression. , 2005, Genomics.
[3] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[4] D. Berry,et al. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Richard Simon,et al. The Use of Genomics in Clinical Trial Design , 2008, Clinical Cancer Research.
[6] Scott M. Berry. A Statistician Reads the Sports Pages , 2003 .
[7] K. Coombes,et al. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology , 2009, 1010.1092.
[8] Christian A. Rees,et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[9] D. Rennie,et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. , 2003, Annals of internal medicine.
[10] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[11] S. P. Fodor,et al. Multiplexed biochemical assays with biological chips , 1993, Nature.
[12] Ronald W. Davis,et al. Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.
[13] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[14] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[15] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[16] Stijn van Dongen,et al. miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..
[17] L. Penland,et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.
[18] D. Berry. Bayesian approaches for comparative effectiveness research , 2012, Clinical trials.
[19] Kevin Coombes,et al. Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy , 2005, Clinical Cancer Research.
[20] R. Peng. Reproducible Research in Computational Science , 2011, Science.
[21] Jeffrey S. Morris,et al. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..
[22] K. Coombes,et al. What information should be required to support clinical "omics" publications? , 2011, Clinical chemistry.
[23] D. Berry,et al. Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials , 2012, Clinical Cancer Research.
[24] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[25] James O. Berger,et al. Statistical Analysis and the Illusion of Objectivity , 1988 .
[26] V. Ambros,et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.
[27] G. Omenn,et al. Evolution of Translational Omics: Lessons Learned and the Path Forward , 2013 .
[28] Stan Pounds,et al. Estimating the Occurrence of False Positives and False Negatives in Microarray Studies by Approximating and Partitioning the Empirical Distribution of P-values , 2003, Bioinform..
[29] Min Zhan,et al. A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.
[30] Chris F. Taylor,et al. Further Steps in Standardisation Report of the Second Annual Proteomics Standards Initiative Spring Workshop (Siena, Italy 17–20th April 2005) , 2005, Proteomics.
[31] Jannik N. Andersen,et al. Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.
[32] Diane D. Liu,et al. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center , 2009, Clinical trials.
[33] David L. Donoho,et al. WaveLab and Reproducible Research , 1995 .
[34] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[35] Edward S. Kim,et al. Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine , 2008, Clinical trials.
[36] S. Stigler. Gauss and the Invention of Least Squares , 1981 .
[37] G. S. Johnson,et al. An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.
[38] Robert Gentleman,et al. Statistical Applications in Genetics and Molecular Biology , 2005 .
[39] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Ana Kozomara,et al. miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..
[41] David M. Simcha,et al. Tackling the widespread and critical impact of batch effects in high-throughput data , 2010, Nature Reviews Genetics.
[42] Stijn van Dongen,et al. miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..
[43] D. Berry. Multiplicities in cancer research: ubiquitous and necessary evils. , 2012, Journal of the National Cancer Institute.
[44] Chunyu Liu,et al. Removing Batch Effects in Analysis of Expression Microarray Data: An Evaluation of Six Batch Adjustment Methods , 2011, PloS one.
[45] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[46] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[47] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[48] L. Lim,et al. An Abundant Class of Tiny RNAs with Probable Regulatory Roles in Caenorhabditis elegans , 2001, Science.
[49] C. Li,et al. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[50] D. Ransohoff,et al. Sources of bias in specimens for research about molecular markers for cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] D. Berry. Adaptive clinical trials: the promise and the caution. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] A. Olshen,et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.
[53] U. Alon,et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[54] R. Simon,et al. Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials , 2004, Clinical Cancer Research.
[55] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[56] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[57] M. Bittner,et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.
[58] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[59] C. Croce,et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[60] D. Berry. Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.
[61] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[62] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[63] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[64] R. Tibshirani,et al. Empirical bayes methods and false discovery rates for microarrays , 2002, Genetic epidemiology.
[65] Daniel J Sargent,et al. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Boris Freidlin,et al. Randomized clinical trials with biomarkers: design issues. , 2010, Journal of the National Cancer Institute.
[67] Cheng Cheng,et al. Improving false discovery rate estimation , 2004, Bioinform..
[68] Use of randomisation in the Medical Research Council's clinical trial of streptomycin in pulmonary tuberculosis in the 1940s , 1998, BMJ.
[69] D Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Annals of internal medicine.
[70] V. Ambros,et al. An Extensive Class of Small RNAs in Caenorhabditis elegans , 2001, Science.
[71] Jason E. Stewart,et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.
[72] L. Chin,et al. Making sense of cancer genomic data. , 2011, Genes & development.
[73] T. Tuschl,et al. Identification of Novel Genes Coding for Small Expressed RNAs , 2001, Science.
[74] Hugues Bersini,et al. Batch effect removal methods for microarray gene expression data integration: a survey , 2013, Briefings Bioinform..
[75] Rafael A Irizarry,et al. Frozen robust multiarray analysis (fRMA). , 2010, Biostatistics.
[76] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[77] Douglas G. Altman,et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration , 2012, PLoS medicine.
[78] D. Bernoulli. Exposition of a New Theory on the Measurement of Risk , 1954 .
[79] K. Baggerly. Disclose all data in publications. , 2010, Nature.
[80] Sarah R. Edmonson,et al. High-resolution serum proteomic patterns for ovarian cancer detection. , 2004, Endocrine-related cancer.
[81] D. Berry,et al. From drug discovery to biomarker-driven clinical trials in lymphoma , 2012, Nature Reviews Clinical Oncology.
[82] J. Matthews,et al. Quantification and the Quest for Medical Certainty , 1995 .
[83] J Jack Lee,et al. Bayesian adaptive randomization designs for targeted agent development , 2008, Clinical trials.